NeuroSense CFO to Present at ROTH Healthcare Conference, Highlighting PrimeC ALS Progress

  • NeuroSense CFO Or Eisenberg to participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026.
  • Company to discuss PrimeC's clinical and regulatory progress in ALS, including Phase 3 PARAGON trial initiation.
  • PrimeC targets neuroinflammation, oxidative stress, and dysregulated iron metabolism in ALS.
  • Phase 2b PARADIGM study results published in JAMA Neurology showed slowing of functional decline relative to placebo.

NeuroSense's participation in the ROTH Healthcare Conference underscores the strategic importance of PrimeC in the ALS treatment landscape. The company's focus on multi-target mechanisms and biomarker validation aligns with broader industry trends toward precision medicine in neurodegenerative diseases. The success of PrimeC could position NeuroSense as a key player in a market with significant unmet needs and growing patient populations.

Clinical Trial Execution
The pace at which NeuroSense advances the Phase 3 PARAGON trial in ALS will determine PrimeC's regulatory timeline.
Regulatory Strategy
Whether NeuroSense can secure regulatory approval in Canada and the U.S. will impact PrimeC's commercial potential.
Investor Sentiment
How institutional investors react to PrimeC's clinical and regulatory progress during the ROTH conference.